Ross L. Levine, MD of Memorial Sloan Kettering Cancer Center to Helm
NEW YORK, NY, February 28, 2018 – The Mark Foundation for Cancer Research, a non-profit organization that funds groundbreaking cancer research, appointed its inaugural Scientific Advisory Committee and announced Ross L. Levine, MD as its first Chair. A physician-scientist and Member of Human Oncology and Pathogenesis Program, Dr. Levine is the Laurence Joseph Dineen Chair in Leukemia Research and Director of Memorial Sloan Kettering’s Center for Hematologic Malignancies. Dr. Levine will also serve as a member of The Mark Foundation’s Board of Directors.
The Scientific Advisory Committee comprises seven distinguished scientists who are recognized as key thought leaders on cancer research. In addition to Dr. Levine, the Committee includes: Scott A. Armstrong, MD, PhD (Dana-Farber Cancer Institute); Curt I. Civin, MD (University of Maryland); Elaine R. Mardis, PhD (Nationwide Children’s Hospital); Jeroen Roose, PhD (University of California, San Francisco); Victor E. Velculescu, MD, PhD (Johns Hopkins University); and E. John Wherry, PhD (University of Pennsylvania.)
With specialties in epigenetics, cancer genomics, stem cell biology, immunotherapy and more, the Committee will review the Foundation’s scientific grant proposals and provide guidance regarding overall funding strategies and investment opportunities.
“I am honored to be joining The Mark Foundation as chair of the Scientific Advisory Committee,” said Dr. Levine. “Funding innovative cancer research and bringing these discoveries to our patients is a very important initiative.”
“We are thrilled to have Ross lead this exceptional team of experts,” said Michele Cleary, PhD, Chief Executive Officer of The Mark Foundation. “Our partnership with them in this endeavor will be critical to achieving the impact for cancer patients and their families to which The Mark Foundation aspires.”
# # #
The Mark Foundation for Cancer Research funds groundbreaking research integrating discoveries in biology with innovative technology to deliver breakthroughs to patients. Established in 2015, The Mark Foundation serves as a premier partner to cancer researchers through an exemplary non-profit business model that combines the funding of high-impact, transformative basic and translational cancer research with venture philanthropy. To learn more about the work of The Mark Foundation for Cancer Research, visit: https://mark.test/